73395-16-1

Upstream product

• 5856-63-3 (2R)-2-aminobutan-1-ol 
• 501-53-1 benzyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 

Downstream Products

• 143915-15-5 (R)-1-oxobutane-2-benzylcarbamate 
• 98289-83-9 (R)-2-benzyloxycarbonylamino-1-tosyloxybutane 
• 950510-38-0 C₁₂H₁₆BrNO₂ 
• 73352-52-0 (2R)-N-(2-benzyloxycarbonylaminobutyloxycarbonyloxy)sucinimide 
• 73352-67-7 (2R)-3,6'-bis-N-benzyloxycarbonyl-1-N-(2-benzyloxycarbonylaminobutyloxycarbonyl)gentamicin B 
• 98289-87-3 (S)-(+)-2-benzyloxycarbonylaminobutane 
• 98289-85-1 (R)-2-benzyloxycarbonylamino-1-iodobutane 
• 73352-52-0 (2R)-N-(2-benzyloxycarbonylaminobutoxycarbonyloxy)succinimide 

Relevant academic research and scientific papers

Highly diastereoselective addition of trimethylsilyl cyanide to chiral hydrazones in the presence of Et2AlCl

Chiral hydrazones, synthesized from (S)-1-amino-2-methoxymethylindoline and aliphatic aldehydes, reacted with trimethylsilyl cyanide in the presence of diethylaluminium chloride in CH2Cl2 at -78°C to give chiral α-hydrazinonitriles w

RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF

Provided are a Rho kinase inhibitor, a method for preparing same and the uses thereof. The Rho kinase inhibitor designates a compound of Formula I, a stereoisomer thereof or pharmaceutically acceptable salt thereof. The Rho kinase inhibitor promotes endothelial cells and endothelin expression, prostenin expression, and vascular factors NO synthesis and secretion, has a promoting effect on proprostin expression independently of the doses used, shows lower toxicity, while being safer.

Carbamate derivatives of felbamate as potential anticonvulsant agents

Several monocarbamate compounds derived from felbamate were synthesized and 11 target compounds (1, 4, and 6-14) were initially evaluated in mice MES and PTZ models in our laboratory. Carbamate compounds with varying substituents on the oxygen (1-4) gave anticonvulsant activity with a wide range of ED 50 in MES test from 300 mg/kg (4) and compounds with different groups on the nitrogen (5-14) also were quite active in the range of 15 mg/kg (14) to 170.5 mg/kg (6). This suggested that the spatial limitation in the MES model seemed flexible especially on the nitrogen end. All tested compounds showed some activity against mice scPTZ test, but none had the ED50 value 50 mg/kg. Ten selected compounds (1 and 6-14) for subsequent pharmacological evaluation in NIH all gave positive mice MES activity except 8 and 9, which were unexpectedly active in rats after further evaluations. Among the compounds, 1, 8, and 9 advanced to the quantitative study and 1 and 9 provided the highest PI values, 15 and 21, respectively, in the rat oral MES test.

Dihydroxyacetone phosphate aldolase catalyzed synthesis of structurally diverse polyhydroxylated pyrrolidine derivatives and evaluation of their glycosidase inhibitory properties

The chemoenzymatic synthesis of a collection of pyrrolidine-type iminosugars generated by the aldol addition of dihydroxyacetone phosphate (DHAP) to C-α-substituted N-Cbz-2-aminoaldehydes derivatives, catalyzed by DHAP aldolases is reported. L-Fuculose-1-phosphate aldolase (FucA) and L-rhamnulose-1-phosphate aldolase (RhuA) from E. coli were used as biocatalysts to generate configurational diversity on the iminosugars. Alkyl linear substitutions at C-α were well tolerated by FucA catalyst (i.e., 40-70% conversions to aldol adduct), whereas no product was observed with C-α-alkyl branched substitutions, except for dimethyl and benzyl substitutions (20%). RhuA was the most versatile biocatalyst: C-α-alkyl linear groups gave the highest conversions to aldol adducts (60-99%), while the C-α-alkyl branched ones gave moderate to good conversions (50-80%), with the exception of dimethyl and benzyl substituents (20%). FucA was the most stereoselective biocatalyst (90-100% anti (3R,4R) adduct). RhuA was highly stereoselective with (S)-N-Cbz-2-aminoaldehydes (90-100% syn (i.e., 3R,4S) adduct), whereas those with R configuration gave mixtures of antilsyn adducts. For iPr and iBu substituents, RhuA furnished the anti adduct (i.e., FucA stereochemistry) with high stereoselectivity. Molecular models of aldol products with iPr and iBu sub-stituents and as complexes with the RhuA active site suggest that the and adducts could be kinetically preferred, while the syn adducts would be the equilibrium products. The polyhydroxylated pyrrolidines generated were tested as inhibitors against seven glycosidases. Among them, good inhibitors of a-L-fucosidase (IC50 = 1-20 μM), moderate of α-L-rhamnosidase (IC50=7-150 μM), and weak of α-D-mannosidase (IC50 = 80-400 μM) were identified. The apparent inhibition constant values (Ki) were calculated for the most relevant inhibitors and computational docking studies were performed to understand both their binding capacity and the mode of interaction with the glycosidases.

NOVEL BETA-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME

1. A β-lactam compound of the formula [1]; ???wherein R1 is a lower alkyl, a lower alkyl substituted by a hydroxy; R2 is a hydrogen, a lower alkyl; X is O, S, NH; m and n are 0 to 4, Y1 is a halogen, cyano, a hydroxy, an amino, a lower alkyloxy, a lower alkylamino, a carboxy, a carbamoyl, a lower alkyl, etc., Y2 is hydrogen, an alkyl, cyano, -C(R3)=NR4 (wherein R3 and R4 are hydrogen, an amino, an alkyl, etc., or R3 and R4 may combine each other together with the nitrogen atom to form a 5- to 7-membered heterocyclic group), or a pharmaceutically acceptable salt thereof, or a non-toxic ester thereof, which has an excellent antibacterial activity against Gram-positive bacteria, especially against MRSA and MRCNS.

A NEW ROUTE TO OPTICALLY PURE cis- AND trans-2,5-DISUBSTITUTED PYRROLIDINES

A new route to optically pure cis- and trans-2,5-disubstituted pyrrolidines is described and is illustrated by the enantiospecific synthesis of (2R,5S)-(+)-2-ethyl-5-heptylpyrrolidine 9 and (2R,5R)-(-)-2-ethyl-5-heptylpyrrolidine 10 starting from (R)-(-)-2-amino-1-butanol 1.

Synthesis of (R)- and (S)-2-Aminobutane from (S)- and (R)-2-Aminobutanol

(R)-(-)- and (S)-(+)-2-Aminobutane (1) can be synthesized in good yield and high optical purity from (S)-(+)- and (R)-(-)-2-aminobutanol (2) respectively.

Semisynthetic Aminoglycoside Antibacterials. Part 10. Synthesis of Novel 1-N-Aminoalkoxycarbonyl and 1-N-Aminoalkylcarboxamido Derivatives of Sisomicin, Gentamicin B, Gentamicin C1a, and Kanamycin A

Suitably protected derivatives of sisomicin, 5-epi-sisomicin, gentamicin B, gentamicin C1a, and kanamycin A have been converted into a series of 1-N-alkoxycarbonyl, 1-N-aminoalkoxycarbonyl, 1-N-carboxamido, 1-N-alkylcarboxamido, and 1-N-aminoal

1-N-substituted derivatives of 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols

Novel 1-N-aminoalkyl (oxycarbonyl or carboxamido or thiocarboxamido) derivatives of 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, useful as antibacterial agents, are described.